Sasko: Drug Policy Makes Treatment More Accessible, Addresses Illegal Export

Bratislava, 6 May (TASR) - The drug policy reform approved by the cabinet on Wednesday aims to increase the availability of innovative medicines on the Slovak market and improve access to treatment, with medicinal products for children and patients with serious illnesses expected to become more accessible, Health Minister Kamil Sasko (Voice-SD) told a press conference on Wednesday, adding that the conditions for the reimbursement of medicines on an 'exception basis' will be changed as well. At the press conference attended by representatives of the entire health-care sector, Sasko said that the proposed amendment also introduces measures to reduce illegal export of medicines. Approval process should be more transparent and subject to clear rules. "We are setting clear deadlines for procedures, conditions for the placement of medicines, medical devices and dietary food on the market, including transparent provision of information in this regard," explained Sasko, noting that the changes are inspired by the Czech legislation. The maximum ceiling for the reimbursement of medicines on an 'exception basis' [medicines not typically covered by health insurance - ed. note.] should be abolished for health insurance companies, while clear criteria have been defined for patient's entitlement to such medicines, which will be binding for all health insurers. As regards illegal re-export, oversight over trading in medicines should be strengthened. Prescription forgery will be considered to be a crime in line with an announced amendment to the law on medicines and medical devices which is expected to be submitted to Parliament for its session in September. Sasko said the drug policy was preceded by a broad discussion with all relevant representatives, including those acting on behalf of patients. The draft amendment should be submitted to Parliament on Friday (8 May), with its second reading expected during the parliamentary session in September. Until then, Sasko is ready to discuss any comments with MPs as well. "I will, of course, respect the opinions of MPs, but they will have to be qualified, not based on populism or lobbying," stressed Sasko, adding that the amendment is slated to become effective in October 2026, with changes regarding the reimbursement of 'exception-based' medicines to enter into force as of January 2027. jrg